RSV Respiratory syncytial virus

RSV: The Disease and Pipeline Vaccines

UPDATED August 27, 2023

Several highly concerning RSV products have now been licensed and approved for use in our most vulnerable populations: pregnant women, newborns and those age 60 and over.

Prepare to be bombarded by marketing messages and pressure from doctors and nurses, who will be unaware of the concerns raised in the clinical trials, the lack of longterm safety studies, or the potential for unintended consequences of the use of the products. Educate yourself on the history of the transitory infection, the factors that increase susceptibility to severe disease, the nutrient and natural prevention and treatment options, naturally acquired immunity, and passive immunity from mother to child.

If you don’t already have a trusted health care provider aligned with your approach to health and wellness, interview health care providers until you find one to serve your needs.

Resources for learning more about the products and RSV treatment information below.


FDA Shrugs Off Concerns About Premature Births, Approves Pfizer RSV Vaccine for Pregnant Women

The U.S. Food and Drug Administration on Monday approved Pfizer’s Abrysvo vaccine, a maternal vaccine meant to protect infants against respiratory syncytial virus, or RSV, through 6 months of age — despite safety concerns, including from the FDA’s own advisers. READ FULL ARTICLE

FDA page for Pfizer’s ABRYSVO (label currently states licensed for those aged 60 and up)



Despite 12 Deaths During Clinical Trials, CDC Signs Off on RSV Shots for Newborns by Michael Nevradakis, Ph.D.

Medical experts criticized the Centers for Disease Control and Prevention’s Thursday decision to recommend a “new immunization” for newborns to protect against respiratory syncytial virus, or RSV, calling the move unnecessary and not worth the known risks. READ FULL DEFENDER ARTICLE

FDA Press Release on AstraZeneca’s BEYFORTUS

FDA product insert for BEYFORTUS

AGED 60+



What is the History of Respiratory Syncytial Virus (RSV) infection in the U.S. and other countries?
“Respiratory Syncytial Virus (RSV) was initially identified in 1955 by JA Morris in laboratory chimpanzees housed at Walter Reed Army Institute of Research in Maryland. The chimpanzees, which were used in polio vaccine research, exhibited symptoms of respiratory illness. Morris was able to confirm that the viral agent, which was initially named Chimpanzee Coryza Agent (CCA), was contagious when he exposed a second group of chimpanzees to the infection” . . . READ MORE.

From Chimpanzees to Children: The Origins of RSV — Respiratory Syncytial Virus


From the FLCCC Alliance:


Download I-CARE RSV and Flu Protocol

A Guide to Diagnosing and Managing Influenza and Respiratory Syncytial Virus (RSV) Infections in Adults
In adult patients, COVID-19 (Omicron variant), influenza, and RSV present with similar symptoms and can, therefore, be difficult to distinguish. This guide aims to help diagnose and treat Influenza and Respiratory Syncytial Virus (RSV).

For advice on how to protect yourself against infection, see I-PREVENT: COVID, Flu and RSV Protection Protocol. For treatment of COVID-19, see I-CARE: Early COVID Treatment Protocol.

BOOK: A Holistic Approach to Viruses by Dr. David Brownstein